Member Info for StarBright

The market will close any arbitrageable gaps without input from the company.

https://www.cityam.com/covid-death-rate-not-rising-swap-travel-restrictions-and-mass-hysteria-for-cautious-optimism-as-omicron-mutation-is-super-mild-variant-who-and-coronavirus-experts-say/

"The WHO and Coronavirus experts are increasingly convinced the new Omicron variant is ‘super mild’ and has, so far, not led to a jump in Covid death rates anywhere in Southern Africa.

The WHO is calling this morning for countries to drop travel restrictions and end the mass hysteria, and instead be cautiously optimistic as more and more reports out of South Africa suggest the new Omicron variant is not more lethal than the previous Delta variant.

In fact, there have been no reports of hospitalisations or deaths as a result of anyone being diagnosed with Omicron."

This is about “tokens” not shares - truly the Wild West of finance. It has nothing to do with GGP and it’s regulated market-makers.

@crl123 - I can detect that you’ve been punched in the face. I can’t identify who did it.

@parkez is spot on, and his clarification is important.

Not only your opinion rxdav. @iceman888 is a poor example of the charismatic mega-ramper, and ramping is not needed here.

What….!?

How could the US “revalue” gold? What impact would they have on a Chinese miner selling to an Indian buyer for example?

And how would that have any impact on (say) on the obligations of the UK to the holders of its bonds…?

The vaccine manufacturers say they don’t yet know whether Omicron is vaccine resistant or not. It is simply irresponsible of you to state otherwise, and you should desist.

https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-says-expect-more-data-new-variant-2-weeks-2021-11-26/

"We understand the concern of experts and have immediately initiated investigations on variant B.1.1.529," BioNTech said in a statement when asked to comment.

"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally," it added.

@HKK - they haven’t confirmed anything regarding vaccine efficacy yet. They don’t know. Read the links you have posted.

Where does it say that the Pfizer, BioNTech and Moderna vaccines don’t work?

You have significant history of posting unsubstantiated doom-laden nonsense regarding the pandemic. Please give it a rest - it is irresponsible to say the least.

Do you not think there is a role for both PCR and LFT? LFT can be used (for example) for screening in schools or for NHS staff, with positive tests followed up with PCR - especially where/when strain identification is an objective.

Remember that an LFT gives a positive result in minutes, which facilitates immediate action (I won't go to school / work today...) whereas PCR typically requires 24-48hrs even with the scale testing labs that have been built.

Despite your apparent perception of their inaccuracy, if you test positive on an LFT, the overwhelming likelihood is that you have COVID. Upwards of 96% of people testing positive on LFTs at the moment will be true positives. This is largely because LFTs are very “specific” – they don’t give many false positives. The UK Health Security Agency estimates that for every 10,000 LFTs taken by genuinely COVID-negative people, there will be fewer than three false positives (a specificity of 99.97%).

Better LFT's are becoming available. Perhaps a combination of these together with PCR will work best?

What do you think...?

@Porky9 - this is precisely where your desire to ramp/promote gets in the way of those looking to use these boards for discussion. @RBMInvest asks a valid question, based on careful reading of an RNS. Your response is nothing but an attempt to wave his question away. Which of NCYT's tests has been authorised clearly matters here. Why not use your knowledge to CONTRIBUTE to discussion - rather than to try desperately to CURATE discussion regardless of the facts? You are so transparent sometimes....

https://www.medrxiv.org/content/10.1101/2021.05.05.21256396v1

Novacyt will be quick to draw attention to any part of their product-set that has specific utility here.

Sure. I think we are in agreement. Let's hope that the NCYT PCR test(s) will be found to be useful for this in the same way as the ThermoFisher assay.

Porky9 assures that they are. But then, he would wouldn't he...! As others have said, a statement on this from the company itself would be useful.

It looks like the "Thermo Fischer TaqPath assay" is the one that can be used as a proxy test. From the WHO document linked above:

" - Most diagnostic tests continue to work and can detect the variant Omicron.
- S gene dropout or S gene target failure (SGTF) due to deletion at Spike position 69-70, similar to the detection of the Alpha variant, has been reported. Thermo Fischer TaqPath assay can therefore be used as proxy test for this variant, pending sequencing confirmation. Use of the SGTF approach may lead to faster detection rates."

That’s my point Soder…!

The WHO statement says “Several labs have indicated that for one widely used PCR test, one of the three target genes is not detected (called S gene dropout or S gene target failure) and this test can therefore be used as marker for this variant, pending sequencing confirmation.”

It would be interesting to know who the manufacturer(s) of the “one widely used PCR test” are.

@parkez said: “ My understanding from reading this. All PCR test can detect this variant along with the other variants.....but only ONE test can distinguish whether its OMICRON or not? Therefore all tests that are positive that have not used this test will be checked against the "marker " test.? The sudden approval suggests its Novas test? Does this make sense?”

I don’t think it is realistic to view the “sudden” approval as evidence that the NCYT PCR has the ability to distinguish Omicron positives from other positives.

I think we know only that the NCYT will give a positive result on Delta or Omicron (or any other known variant) infected samples.

We don’t know that it will distinguish between Delta or Omicron positive tests. It may be that separate follow-up sequencing is required for this.

This seems to be a critical question. I would be very happy to be proved wrong, so would welcome further input / other views.

£54.

100% agreed BigMinnow. It would be better to wait and see what the analysis says, before trying to spin it to justify a somewhat distasteful investment hypothesis.

Who remembers the Danish Mink variant that induced a flurry of political grandstanding last year?

Your politics are showing again Regulator…